![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » ELAN GRANTS ABBOTT, ASTRAZENECA NANOCRYSTAL TECHNOLOGY RIGHTS
ELAN GRANTS ABBOTT, ASTRAZENECA NANOCRYSTAL TECHNOLOGY RIGHTS
July 6, 2006
Abbott Pharmaceutical and AstraZeneca have been granted the U.S rights to use Irish drugmaker Elan's NanoCrystal technology to develop fixed-dose combination products.
Under the terms of the agreement, Elan will receive payments upon the achievement of development, clinical, and regulatory milestones for such new products.
Additionally, Elan will receive royalty payments based on U.S sales of the products if successfully developed and commercialized.
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct